NASDAQ: XLRN - Acceleron Pharma Inc.

Yield per half year: 0%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Acceleron Pharma Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Acceleron Pharma Inc.

Acceleron Pharma Inc., биофармацевтическая компания, специализируется на открытии, разработке и коммерциализации терапевтических средств для лечения серьезных и редких заболеваний. Он предлагает люспатерсепт-амт для лечения анемии у взрослых пациентов с бета-талассемией под названием REBLOZYL.

more details
Компания также разрабатывает люспатерсепт-амт для лечения миелодиспластических синдромов и миелофиброза; Сотатерсепт для лечения пациентов с легочной артериальной гипертензией; и ACE-083, нервно-мышечный кандидат, который находится в фазе II клинических испытаний для лечения пациентов с болезнью Шарко-Мари-Тута. Кроме того, у него есть соглашение о сотрудничестве, лицензия и опционное соглашение с Celgene Corporation; а также сотрудничество и лицензионное соглашение с Fulcrum Therapeutics, Inc. для выявления небольших молекул, предназначенных для модуляции определенных путей, связанных с целевым показанием в области легочных заболеваний. Ранее компания называлась Phoenix Pharma, Inc. Acceleron Pharma Inc. была основана в 2003 году, ее штаб-квартира находится в Кембридже, штат Массачусетс.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2013-09-19
ISIN US00434H1086
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://www.acceleronpharma.com
Цена ао 178.75
Change price per day: 0% (178.75)
Change price per week: 0% (178.75)
Change price per month: 0% (178.75)
Change price per 3 month: 0% (178.75)
Change price per half year: 0% (178.75)
Change price per year: 0% (178.75)
Change price per 3 year: 0% (178.75)
Change price per 5 year: +69.75% (105.3)
Change price per 10 year: +454.78% (32.22)
Change price per year to date: 0% (178.75)
All parameters

Underestimation

Title Value Grade
P/S 96.1 1
P/BV 15.2 1
P/E 0 0
EV/EBITDA -41.24 0
Total: 1.25

Efficiency

Title Value Grade
ROA, % -29.37 0
ROE, % -31.59 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.08 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 735.56 10
Yield Ebitda, % 137.31 10
Yield EPS, % 55.97 7
Total: 9.4
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
27.09.2021 27.09.2021 KANGO SUJAY
EVP, Chief Commercial Officer		 Sale 175 875 000 5000 0 -0.01 link
27.09.2021 27.09.2021 KANGO SUJAY
EVP, Chief Commercial Officer		 Purchase 40.61 203 050 5000 0 0.01 link
24.09.2021 24.09.2021 MCLAUGHLIN KEVIN F
SVP, CFO and Treasurer		 Sale 160.38 861 241 5370 0 -0.01 link
24.09.2021 24.09.2021 MCLAUGHLIN KEVIN F
SVP, CFO and Treasurer		 Purchase 40.64 218 237 5370 0 0.01 link
23.09.2021 24.09.2021 MCLAUGHLIN KEVIN F
SVP, CFO and Treasurer		 Sale 160.31 3 146 880 19630 0 -0.03 link
23.09.2021 24.09.2021 MCLAUGHLIN KEVIN F
SVP, CFO and Treasurer		 Purchase 39.67 778 722 19630 0 0.03 link
02.07.2021 02.07.2021 Dable Habib J
CEO and President		 Sale 126.97 5 356 360 42186 0 -0.08 link
02.07.2021 02.07.2021 Dable Habib J
CEO and President		 Purchase 35.04 1 478 200 42186 0 0.08 link
01.07.2021 02.07.2021 Dable Habib J
CEO and President		 Sale 126.73 7 326 770 57814 0 -0.11 link
01.07.2021 02.07.2021 Dable Habib J
CEO and President		 Purchase 35.04 2 025 800 57814 0 0.11 link
11.12.2020 11.12.2020 MCLAUGHLIN KEVIN F
SVP, CFO and Treasurer		 Sale 125 387 500 3100 0 -0.01 link
10.12.2020 11.12.2020 MCLAUGHLIN KEVIN F
SVP, CFO and Treasurer		 Sale 125.12 62 560 500 0 0 link
09.12.2020 11.12.2020 MCLAUGHLIN KEVIN F
SVP, CFO and Treasurer		 Sale 125.03 484 116 3872 0 -0.01 link

Institutions Volume Share, %
Fidelity Management & Research Company LLC 3487318 5.79
BlackRock Fund Advisors 3414190 5.62
venBio Select Advisor LLC 3000000 4.91
Fidelity SelectCo, LLC 2685757 4.39
Fidelity Management & Research Company LLC 2656932 4.35
Darwin Global Management, Ltd. 1760346 2.88
Artal Group S A 1400000 2.31
Westend Sa 1400000 2.29
Baron Capital Management Inc 1155017 1.89
Fidelity Investments 573672 0.94
Candriam Belgium 555719 0.91
Artisan Partners Holdings LP 531970 0.88
Columbia Wanger Asset Management LLC 441684 0.72
Principal Global Investors, LLC 338617 0.55
Polar Capital LLP 337513 0.55
Brown Advisory LLC 335263 0.55
Harbor Capital Advisors Inc 323821 0.53
IndexIQ Advisors LLC 247072 0.4
AXA Investment Managers UK Ltd 186911 0.31
Putnam Investment Management, LLC 183888 0.3
Prudential Retirement Services 174917 0.29
UBS Fund Management (Luxembourg) S.A. 156714 0.26
AMG Funds LLC 142909 0.24
Invesco Capital Management LLC 137924 0.23
Octagon Capital Advisors LP 112363 0.18
Foresite Capital Management III, LLC 108630 0.18
Granahan Investment Management Inc 91177 0.15
ALPS Advisors Inc 70095 0.11
Security Investors, LLC 53004 0.09
Baillie Gifford Overseas Limited 45460 0.07
Kennedy Capital Management 42733 0.07
Odey Asset Management LLP 33800 0.06
UBS Asset Management 23630 0.04
Secure Fondsmæglerselskab A/S 18300 0.03
PMG Fonds Management AG 17200 0.03
First Trust Portfolios L.P. 4403 0.01
Peroni Portfolio Advisors, Inc 600 0
Zeus Asset Management S.A. 460 0
Pence Capital Management, LLC. 400 0
Hennion & Walsh, Inc 200 0
Hennion & Walsh, Inc 100 0



Head Job title Payment Year of birth
Mr. Habib J. Dable CEO, Pres & Director 1.26M 1969 (56 years)
Mr. Kevin F. McLaughlin Sr. VP, CFO & Treasurer 712.08k 1956 (69 years)
Mr. Adam M. Veness Esq. Sr. VP, Gen. Counsel & Sec. 690.62k 1986 (39 years)
Mr. Sujay R. Kango Exec. VP & Chief Commercial Officer 702.16k 1964 (61 year)
Dr. Jay T. Backstrom M.D., M.P.H. Exec. VP of R&D 850k 1955 (70 years)
Dr. Thomas P. Maniatis Co-Founder, Member of Scientific Advisory Board & Director Emeritus N/A 1943 (82 years)
Dr. Mark Ptashne Co-Founder and Member of Scientific Advisory Board N/A
Ms. Lisa Wyman Sr. VP of Technical Operations N/A
Dr. Ravindra Kumar Chief Scientific Officer & Sr. VP N/A 1960 (65 years)
Mr. Todd James IRC Sr. VP of Corp. Affairs & Investor Relations N/A

Address: United States, Cambridge, 128 Sidney Street - open in Google maps, open in Yandex maps
Website: http://www.acceleronpharma.com